医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Research and Markets: Ulcerative Colitis (Event Driven)

2012年09月26日 AM02:07
このエントリーをはてなブックマークに追加


 

DUBLIN

Research and Markets (http://www.researchandmarkets.com/research/9kvfqr/ulcerative) has announced the addition of Decision Resources, Inc’s new report “Ulcerative Colitis (Event Driven)” to their offering.

Although colectomy is curative for the potentially fatal immune disease ulcerative colitis (UC), this procedure is life altering, and therefore unmet need remains for additional pharmacotherapies that more effectively treat moderate to severe disease and maintain disease remission better than do existing drugs. The increasing use of tumor necrosis factor-alpha (TNF-a) inhibitors and the uptake of two emerging therapies with a novel mechanism of action among patients with moderate to severe disease will drive strong growth of the UC market throughout our 2010-2020 forecast period, while innovative reformulations of current therapies will expand treatment options for patients with mild to moderate UC.

Key Topics Covered:

– Executive Summary

– 1 Etiology and Pathophysiology

– 2 Epidemiology and Patient Populations

– 3 Current Therapies and Medical Practice

– 4 Unmet Needs

– 5 Emerging Therapies

– 6 Market Outlook

– Appendix A BibliographyUlcerative Colitis

– Appendix B Market Forecast Methodology

– Appendix C Experts InterviewedUlcerative Colitis

– Appendix D Supplemental Epidemiology Bibliography

– Tables and Figures

For more information visit http://www.researchandmarkets.com/research/9kvfqr/ulcerative

Source: Decision Resources, Inc

CONTACT

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Healthcare
and Medical Devices
, Pharmaceuticals

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Scientist.comが東京に新事務所を開設してアジア太平洋地域に拡大
  • HIMSSがHealthcare IT NewsとMobiHealth Newsの海外展開を発表
  • 科克斯巴扎尔医院将为14万罗兴亚难民提供全天候医疗救助
  • HeartFlow Receives National Reimbursement Approval in Japan
  • 关于术后贫血处治的国际共识声明推荐包括Masimo SpHb®在内的血红蛋白无创测量